Providing systematic guidance in pharmacoeconomic guidelines for analysing costs

PharmacoEconomics

Volumn 23, Issue 2, 2005, Pages 143-153

  Jacobs, Philip ^a   Ohinmaa, Arto ^a   Brady, Bruce ^b  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b Canadian Coordinating Office for Health Technology Assessment   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; COST CONTROL; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STANDARD;

COSTS AND COST ANALYSIS; ECONOMICS, PHARMACEUTICAL; GUIDELINES; HEALTH CARE COSTS; HUMANS;

EID: 16244415190     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523020-00006     Document Type: Review

References (22)

1. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Australia: Commonwealth Department of Health and Ageing, 2002
2. Ontario Ministry of Health and Long Term Care. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: the Ministry, 1994 Aug
3. Jacobs P, Bachynsky J. Costing methods in the Canadian literature on the economic evaluation of health care: a survey and assessment. Int J Technol Assess Health Care 1996; 12 (4): 721-34
4. Adam T, Koopmanschap MA. Cost-effectiveness analysis: can we reduce variability in costing methods? Int J Technol Assess Health Care 2003; 19 (2): 407-20
5. Baron F. Pharmacoeconomic guidelines: per country and international comparisons, current situation and perspectives. Lyon, France: GYD Institute, 2000
6. Graf von der Schulenburg JM, Hoffmann C. Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals. Eur J Heath Econ (HEPAC) 2000; 1: 2-8
7. Hjelmgren J, Berggren F, Andersson F F. Health economic guidelines: similarities, differences and some implications. Value Health 2001; 4 (3): 225-50
8. Gold M, Siegel J, Russell LB, et al. Cost: effectiveness in health and medicine. New York: Oxford University Press, 1996
9. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
10. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardisation of costs: the Dutch manual for costing in economic evaluation. Pharmacoeconomics 2000; 20 (7): 443-54
11. Guidelines for preparation of an account of health economic aspects. Helsinki: Ministry of Social Affairs and Health; 1999. Available from URL: http://www.stm.fi/hila/english/hecon 99.doc [Accessed 19 Sep 2003]
12. Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. 2002. Available from URL: http://www. legemiddelverket.no/eng/reg/pharmacoeconomic-analysis-guidelines. htm [Accessed 2003 Jul 2]
13. Health Technology Board for Scotland. Guidance for manufacturers on submission of evidence relating to clinical and cost effectiveness in Health Technology Assessments. Glasgow: NHS Quality Improvement Scotland: 2002. Available from URL: http: //www.htbs.co.uk/docs/pdf/0050%20(Guidance %20 for%20manufacturers%20published).pdf [Accessed 2003 Sep 19]
14. Guidelines for the economic evaluation of pharmaceuticals. 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997
15. Recommendations de bonnes pratiques des méthodes d'évaluation économique des stratégiques thérapeutiques. Journal d'Economie Medicale. Available from URL: http://perso. wanadoo.fr/ces/Pages/guidelin.htm [Accessed 2003 Jul 4]
16. Garattini L, Grilli R, Scopelliti D, et al. A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 1995; 7 (1): 1-6
17. Rovira J, Antonanzas F. Economic analysis of health technologies and programmes: a Spanish proposal for methodological standardization. Pharmacoeconomics 1995; 8 (3): 245-52
18. National Insititute for Clinical Excellence. New technology appraisal guidance documents. London: National Institute for Clinical Excellence, 2001
19. Lin DY, Feuer EJ, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics 1997; 53: 419-34
20. Commonwealth Department of Health and Aging. Manual of resource items and their associated costs. Canberra, Australia: Commonwealth Department of Health and Ageing, 2002. 1992
21. Brouwer WB, Koopmanschap MA, Rutten FF. Patient and informal caregiver time in cost-effectiveness analysis: a response to the recommendations of the Washington Panel. Int J Technol Assess Health Care. 1998 Summer; 14 (3): 505-13
22. Halliday RG, Darba J. Cost data assessment in multinational economic evaluations: some theory and review of published studies. Appl Health Econ Health Policy 2003; 2: 149-55